Drugs / KUS121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06178055 | Apr 2024 → Mar 2025 | central retinal artery occlusion | Kyoto Drug Discovery and Development Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KUS121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06178055 ↗ |
| Route | Intravitreal | “Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).” NCT06178055 ↗ |